Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Options to Reduce Cardiovascular Events in Atherosclerotic Cardiovascular Disease (ASCVD)

New Options to Reduce Cardiovascular Events in Atherosclerotic Cardiovascular Disease (ASCVD)
Join a panel of experts as they break down the challenges faced—and challenges overcome—when treating patients’ residual cardiovascular disease risk.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues when treating patients with residual cardiovascular disease (CVD) risk, using triglyceride-rich lipoprotein (TGRL) science and management. The program is based on a live satellite symposium (held during the time of AHA-2018), where REDUCE-IT results were 1st presented after a late-breaking clinical trial presentation. Challenges faced by healthcare providers in caring for patients with elevated TGRL are addressed. Topics include:

    • Central Role of Triglyceride-rich Lipoproteins (TGRL) in CVD Residual Risk beyond Statin Therapy
    • Biologic Basis for TGRL Modulation in Reducing Atherosclerosis
    • Clinical Evidence on Reducing TGRL-based Residual Risk: REDUCE-IT

    For more information, contact Medtelligence, LLC at

  • Provider(s)/Educational Partner(s)

    Jointly provided by Postgraduate Institute for Medicine ( and Medtelligence.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma Inc.

  • Target Audience

    This activity is intended for Cardiologists (General), Clinical Cardiologists, Internal Medicine/Primary Care Physicians, NPs/PAs, Fellows, Nurses, and other healthcare professionals engaged in the management of CVD.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    • Recognize the importance of managing cardiovascular disease (CVD) residual risk beyond lowering LDL-C
    • Discuss the contribution of triglyceride-rich lipoproteins (TGRL) in the formation of atherogenic plaques and eventual atherothrombosis
    • Describe the anti-atherosclerotic properties of TGRL-lowering therapies
    • Relate the clinical and genetic evidence for the association between elevated triglycerides/remnant lipoproteins and atherosclerosis
  • Faculty

    Peter Libby, MD, Co-Chair
    Cardiovascular Medicine Specialist
    Brigham and Women’s Hospital
    Mallinckrodt Professor of Medicine
    Harvard Medical School
    Boston, MA

    Michael Miller, MD, Co-Chair
    Professor of Cardiovascular Medicine, Epidemiology & Public Health
    University of Maryland School of Medicine
    Director, Center for Preventive Cardiology
    University of Maryland Medical Center
    Baltimore, MD

    Deepak L. Bhatt, MD, MPH
    Executive Director, Interventional Cardiovascular Programs
    Brigham and Women’s Hospital Heart & Vascular Center
    Professor of Medicine
    Harvard Medical School
    Boston, MA

    R. Preston Mason, PhD
    Cardiovascular Division
    Brigham and Women’s Hospital
    Harvard Medical School
    Boston, MA
    Scientific Director and Founder
    Elucida Research
    Beverly, MA

    Børge G. Nordestgaard, MD, DMSc
    Chief Physician in Clinical Biochemistry
    Copenhagen University Hospital
    Herlev, Denmark
    Professor in Genetic Epidemiology
    University of Copenhagen
    Copenhagen, Denmark

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


    • Deepak L. Bhatt, MD, MPH: Contracted Research: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company.
    • Peter Libby, MD: Salary: Brigham & Women’s Hospital; Unpaid consultant to, or involved in clinical trials for: Amgen, AstraZeneca, Esperion, Ionis, Kowa, Novartis, Pfizer, Sanofi-Regeneron, Takeda, XBiotech; Scientific Advisory Board: Amgen, Athera, Corvidia, DalCor, IFM Therapeutics, Kowa, Olatec, Medimmune, Novartis; Research funding (laboratory): Novartis.
    • R. Preston Mason, PhD: Consulting Fees: Amarin, Pfizer; Contracted Research: ARCA, Amarin, Amgen, Pfizer, Novartis.
    • Michael Miller, MD: Consulting Fees: Amarin: Steering Committee REDUCE IT trial. 
    • Børge G. Nordestgaard, MD, DMSc: Consulting Fees: Amgen, Regeneron, Sanofi, Akcea, Kowa, AstraZeneca.

    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose.

  • Method of Participation and Request for Credit

    There are no fees for participating and receiving CME credit for this activity. During the period November 12, 2018 through November 12, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, complete the post-test and evaluation. Participants who successfully complete the activity, post-test, and evaluation will have a statement of credit made available immediately.

    If you have any questions regarding the CME certification of this activity, please contact Postgraduate Institute for Medicine at: or (303) 799-1930.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • Additional Information

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 12/15/19